US 11357832
Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
granted A61KA61K38/46A61K38/465
Quick answer
US patent 11357832 (Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase) held by Takeda Pharmaceutical Company Limited expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K38/46, A61K38/465, A61K9/0019, A61K9/0085